Qol Holdings (3034) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
21 Jul, 2026Executive summary
Achieved record-high sales, operating profit, and ordinary profit for the three months ended June 30, 2024, driven by consolidation of DAIICHI SANKYO ESPHA and strong segment performance.
Net profit increased overall, but profit attributable to owners of parent decreased 16.6% to ¥843 million due to extraordinary loss from step acquisition accounting and increased non-controlling interests.
EBITDA surged 54.2% to ¥4,837 million year-over-year.
Financial highlights
Net sales rose 40.6% year-over-year to ¥61,036 million.
Operating profit increased 55.6% year-over-year to ¥2,915 million.
Ordinary profit grew 52.9% year-over-year to ¥2,966 million.
Profit increased 42.3% year-over-year to ¥1,434 million.
Net income per share decreased 17.0% year-over-year to ¥22.59.
Outlook and guidance
First quarter results exceeded forecasts, with net sales at 100.3%, operating profit at 135.0%, ordinary profit at 134.3%, and profit at 160.8% of plan.
Full-year net sales forecast is ¥270,000 million, with operating profit projected at ¥15,000 million and profit attributable to owners of parent at ¥5,700 million.
Dividend forecast for FY2025 is ¥34.00 per share, up from ¥30.00 in the prior year.
Latest events from Qol Holdings
- Net sales and operating profit surged on consolidation, but net profit declined on higher non-controlling interests.3034
Q2 202521 Jul 2026 - Record sales and profit achieved; robust outlook and higher dividends forecast.3034
Q4 202521 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and DAIICHI SANKYO ESPHA.3034
Q2 202621 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and BPO growth, with ROE at 12.9%.3034
Q4 202621 Jul 2026 - Record sales and operating profit achieved, but parent profit declined due to higher costs and minority interests.3034
Q3 202521 Jul 2026 - Record-high quarterly sales and profits driven by pharmacy, AG product growth, and acquisition.3034
Q1 202621 Jul 2026 - Record-high sales and profit attributable to owners, with strong segment growth and stable outlook.3034
Q3 202621 Jul 2026